CPC
NVCR icon

Cookson Peirce & Co’s NovoCure NVCR Stock Holding History

Cookson Peirce & Co’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-174,042
Closed -$30.1M – 198
2020
Q4 		$30.1M Buy
174,042
+166,273
+2,140% +$22.8M 2.05% 15
2020
Q3 		$865K Buy
+7,769
New +$621K 0.07% 94

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cookson Peirce & Co's NVCR Position: Q1 2021 in Review

Cookson Peirce & Co sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 174,042 shares — an estimated $30.1M sold.

Cookson Peirce & Co first reported a position in NVCR in Q3 2020 and held it in 2 quarters. The position peaked at $30.1M in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Cookson Peirce & Co reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Cookson Peirce & Co sold 174,042 NovoCure shares in Q1 2021, an estimated $30.1M.
  • Cookson Peirce & Co first reported a position in NovoCure in Q3 2020 and held it in 2 quarters.
  • Cookson Peirce & Co's NovoCure position peaked at $30.1M in Q4 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Cookson Peirce & Co's 13F filing for Q1 2021, filed 11 May 2021.